Visualizing the Blueprint of DNA Damaging in Ovarian Cancer by Therapeutic Agents 1


Submitted by Lawrence Mensah and Paula Hammond of the Koch Institute for Integrative Cancer Research at MIT


The current treatment for ovarian cancer is the use of potent DNA damaging agent, Cisplatin as a monotherapy. Recently PARP inhibitors have been developed, but also used as a monotherapy for a number of solid tumors. The goal of my research is to test the combination of Cisplatin and PARP inhibitor to induce ‘synthetic lethality’ for ovarian cancer treatment.